Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Trial Profile

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease; Dementia; Diagnostic-imaging-abnormalities; Mild cognitive impairment
  • Focus Diagnostic use
  • Most Recent Events

    • 26 Oct 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
    • 23 Mar 2016 No of arms changed from 2 to 1 as per record.
    • 23 Mar 2016 Planned number of patients changed from 160 to 100 as per record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top